Abstract
To assess the relationship between serological markers of thyroid autoimmunity and chronic hepatitis C, we surveyed the general population of two villages in the region of Sardinia, Italy, where infection with hepatitis viruses is endemic and the prevalence of autoimmune diseases is elevated. A total of 1310 subjects aged 6–88 years (65% of the total resident population) participated in the survey, and 1233 (94%; 444 males and 789 females) agreed to provide a blood sample. Autoantibodies to thyroid peroxidase (anti-TPO) were measured by radioimmunoassay; antibodies to HCV (anti-HCV) by a third generation enzyme immunoassay and borderline positive results confirmed by recombinant immunoblot assay. For both anti-HCV and anti-TPO the ageand gender-standardized prevalence rates (SPR) were calculated and the significance of the association between the two antibodies tested by Yates corrected χ2 test. The overall SPR for anti-HCV was 50.7×10−3 (86/1,233), similar between men [49.1×10−3 (22/444)] and women [52.3×10−3 (64/789)]. The overall SPR for anti-TPO was 136.9×10−3 (204/1,233), and that among women [201×10−3 (174/789)] was almost 3-fold that among men [71.6×10−3 (30/444)]. A concurrent anti-HCV and anti-TPO positivity was found in a small minority of subjects [8/1,233 (0.65%)], all women aged 57–81 years. The SPR for the two concurrent events was 3.3×10−3, which was not significantly different (Yates corrected χ2 test = 0.65) from that expected under the assumption of unrelated events. To explore whether HCV infection is a risk factor for anti-TPO positivity, we designed a casecontrol study with anti-TPO positive subjects as the cases, and anti-TPO negative subjects as the controls. The age- and gender-adjusted odd ratio (OR) was 0.4 (95% CI 0.2,0.7), indicating a negative association. In conclusion, no evidence for epidemiological association of circulating thyroid autoantibodies and antibodies to HCV was found. Our findings do not therefore support a pathogenetic link between HCV infection and thyroid autoimmunity.
Similar content being viewed by others
References
Tomer Y., Davies T.F. Infections and autoimmune endocrine disease. Baillière Clin. Endocrinol. Metab. 1995, 9: 47–70.
Huang M.J., Liaw Y.F. Clinical associations between thyroid and liver diseases. J. Gastroenterol. Hepatol. 1995, 10: 344–350.
Tran A., Quaranta J.F., Benzaken S., Thiers V., Chau H.T., Hastier P., Regnier D., Dreyfus G., Pradier C., Sadoul J.L., Hebuterne X., Rampal P. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis- C before interferon therapy. Hepatology 1993, 18: 253.
Pawlotsky J.M., Roudotthoraval F., Simmonds P., Mellor J., Benyahia M., Andre C., Voisin M.C., Intrator L., Zafrani E.S., Duval J., Dhumeaux D. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann. Intern. Med. 1995, 122: 169–173.
Clifford B.D., Donahue D., Smith L., Cable E., Luttig B., Manns M., Bonkovsky H.L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995, 21: 613–619.
Mandrup-Poulsen T., Nerup J., Reimers J.I., Pociot F., Andersen H.U., Karlsen A., Bjerre U., Bergholdt R. Cytokines and the endocrine system. 2. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Eur. J. Endocrinol. 1996, 134: 21–30.
Lunel F. Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology 1994, 108: 1334.
Heathcote E.J. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy? Gastroenterology 1995, 108: 1942.
Nagayama Y., Ohta K., Tsuruta M., Takeshita A., Kimura H., Hamasaki K., Ashizawa K., Nakata K., Yokoyama N., Nagataki S. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: Our studies and review of the literature. Endocrinol. J. 1994, 41: 565–572.
Pateron D., Hartmann D.J., Duclosvallee J.C., Jouanolle H., Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J. Hepatol. 1993, 17: 417–419.
Preziati D., La Rosa L., Covini G., Marcelli R., Rescalli S., Persani L., Del Ninno E., Meroni P.L., Colombo M., Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 1995, 132: 587–593.
Custro N., Montalto G., Scafidi V., Soresi M., Gallo S., Tripi S., Notarbartolo A. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J. Endocrinol. Invest. 1997, 20: 374–380.
Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F., Vazquez R., Ocete E., Olea N., Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch. Intern. Med. 1998, 158: 1445–1448.
Olivieri A., Sorcini M., Battisti P., Fazzini C., Gilardi E., Sun Y., Medda E., Grandolfo M., Tossini G., Natili S., Gioia C., Narciso P., Visco G., Carta S. Thyroid hypofunction related with the progression of human immunodeficiency virus infection. J. Endocrinol. Invest. 1993, 16: 407–413.
Huang M.J., Wu S.S., Liaw Y.F. Thyroid abnormalities in patients with chronic viral hepatitis. Hepatology 1994, 20: 1651–1652.
Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B., Garcia-Monzon C., Arranz A., Borque M.J., Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin. Endocrinol. (Oxf). 1996, 44: 635–642.
Duclos-Vallée J.C., Johanet C., Trinchet J.C., Deny P., Laurent M.F., Duron F., Valensi P., Weil B., Homberg J.C., Pateron D., Beaugrand M. High prevalence of serum antibodies to hepatitis C virus in patients with Hashimoto’s thyroiditis. BMJ 1994, 309: 846–847.
Wagner B., Vierhapper H., Hofmann H. Prevalence of hepatitis C virus infection in Hashimoto’s thyroiditis. BMJ 1996, 312: 640–641.
Wong S., Mehta A.E., Faiman C., Berard L., Ibbott T., Minuk G.Y. Absence of serologic evidence for hepatitis C virus infection in patients with Hashimoto’s thyroiditis. Hepatogastroenterology 1996, 43: 420–421.
Boadas J., Rodriguez-Espinosa J., Enriquez J., Miralles F., Martinez-Cerezo F.J., Gonzalez P., Madoz P., Vilardell F. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J. Hepatol. 1995, 22: 611–615.
Farci P., Orgiana G., Coiana A., Peddis G., Mandas A., Lai M.E., Farci A.M.G., Chessa L., Balestrieri A. Epidemiology of HDV infection in Sardinia, an island with high endemicity for HBV: a multicenter study. In: Gerin J.L., Purcell R.H., Rizzetto M., (Eds), Progress in Clinical and Biological Research, the Hepatitis Delta Virus. Alan Liss, Inc., New York, 1991, p.40–50.
Muntoni S., Songini M. Sardinian Collaborative Group for Epidemiology of IDDM: high incidence of IDDM in Sardinia. Diabetes Care 1992, 15: 1317–1322.
Marrosu M.G., Muntoni F., Murru M.R., Costa G., Pischedda M.P., Pirastu M., Sotgiu S., Rosati G., Cianchetti C. HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1 *0201 and *0302 alleles. Neurology 1992, 42: 883–886.
Mariotti S., Caturegli P., Piccolo P., Barbesino G., Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. J. Clin. Endocrinol. Metab. 1990, 71: 661–669.
Di Mario U., Betterle C., Dondero F., Fenzi G.F., Mariotti S., Trimarchi F. Italian serum exchange workshop for the standardization of organ specific autoantibodies. J. Endocrinol. Invest. 1994, 17: 355–365.
Lai M.E., Mazzoleni A.P., Farci P., Melis A., Porru A., Orgiana G., Arnone M., Balestrieri A. Markers of hepatitis C virus infection in sardinian blood donors: relationship with alanine aminotransferase levels. J. Med. Virol. 1993, 41: 282–288.
Rosner B. Fundamental of Biostatistics. Duxbury Press Inc., Boston, 1986.
Miettinen O. Estimability and estimation in case-referent studies. Am. J. Epidemiol. 1976, 103: 226–235.
Tillmann H.L., Manns M.P. Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig. Dis. Sci. 1996, 41: 27, 27S–40S.
Tunbridge W.M.G., Evered D.C., Hall R., Appleton D., Brewis M., Clark F., Grimley Evans J., Young E., Bird T., Smith P.A. The spectrum of thyroid disease in a community: the Wickham survey. Clin.Endocrinol. (Oxf). 1977, 7: 481–493.
Hawkins B.R., Cheah P.S., Dawkins R.L., Whittingham S., Burger H.G., Patel Y., Mackay I.R., Welborn T.A. Diagnostic significance of thyroid microsomal antibodies in randomly selected population. Lancet 1980, 2: 1057–1059.
Konno N., Yuri K., Taguchi H., Miura K., Taguchi S., Hagiwara K., Murakami S. Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin assays, and serum thyroid autoantibody and urinary iodide determinations. Clin. Endocrinol. (Oxf). 1993, 38: 273–281.
Salabè-Lotz H., Salabè G.B. Population survey of thyroid autoimmunity in Italy. Three-year follow up. Thyroidology 1990, 2: 107–112.
Mariotti S., Sansoni P., Barbesino G., Caturegli P., Monti D., Cossarizza A., Giacomelli T., Passeri G., Fagiolo U., Pinchera A., Franceschi C. Thyroid and other organ-specific autoantibodies in healthy centenarians. Lancet 1992, 339: 1506–1508.
Quaranta J.F., Tran A., Regnier D., Letestu R., Beusnel C., Fuzibet J.G., Thiers V., Rampal P. High prevalence of antibodies to hepatitis-C virus (HCV) in patients with anti-thyroid autoantibodies. J. Hepatol 1993, 18: 136–138.
Baudin E., Marcellin P., Pouteau M., Colas-Linhart N., Lefloch J.P., Lemmonier C., Benhamou J.P., Bok B. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. (Oxf). 1993, 39: 657–661.
Colas-Linhart N., Bok B., Marcellin P., Pouteau M., Benhamou J.P. Anti-thyroid autoantibodies and hepatitis C virus. Hepatology. 1994, 20: 1649.
Czaja A.J., Carpenter H.A., Santrach P.J., Moore S.B. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J. Hepatol. 1996, 24: 52–59.
Metcalfe R.A., Ball G., Kudesia G., Weetman A.P. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 1997, 7: 421–424.
Alberti A., Morsica G., Chemello L., Cavalletto D., Noventa F., Pontisso P., Ruol A. Hepatitis C viraemia and liver disease in symptomfree individuals with anti-HCV. Lancet 1992, 340: 697–698.
Bortolotti F., Vajro P., Balli F., Giacchino R., Crivellaro C., Barbera C., Cataleta M., Mratori L., Pontisso P., Nebbia G., Zancan L., Bertolini A., Alberti A., Bianchi F. Non-organ specific autoantibodies in children with chronic hepatitis C. J. Hepatol. 1996, 25: 614–620.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Loviselli, A., Oppo, A., Velluzzi, F. et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: Results of a community-based study in northwestern Sardinia. J Endocrinol Invest 22, 660–665 (1999). https://doi.org/10.1007/BF03343626
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343626